Nuclear factor, erythroid 2-like 2-associated molecular signature predicts lung cancer survival

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Qian, Zhongqing ^a,b   Zhou, Tong ^b   Gurguis, Christopher I ^b   Xu, Xiaoyan ^b   Wen, Qing ^c,d   Lv, Jingzhu ^a   Fang, Fang ^a   Hecker, Louise ^b,e   Cress, Anne E ^b   Natarajan, Viswanathan ^f   Jacobson, Jeffrey R ^f   Zhang, Donna D ^d   Garcia, Joe G N ^b   Wang, Ting ^b  

^a BENGBU MEDICAL COLLEGE   (China)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c JINAN CENTRAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^d UNIVERSITY OF ARIZONA   (United States)

^e SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

^f UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NFE2L2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR NRF2; TRANSCRIPTOME;

ADENOCARCINOMA; GENE EXPRESSION; GENETICS; HUMAN; KAPLAN MEIER METHOD; LUNG TUMOR; META ANALYSIS; METABOLISM; MORTALITY; PHYSIOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; GENE EXPRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; NF-E2-RELATED FACTOR 2; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TRANSCRIPTOME;

EID: 84948126735     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep16889     Document Type: Article

References (51)

1. Biswas, C. et al. Nuclear heme oxygenase-1 (HO-1) modulates subcellular distribution and activation of Nrf2, impacting metabolic and anti-oxidant defenses. The Journal of biological chemistry 289, 26882-26894, doi: 10.1074/jbc.M114.567685 (2014).
2. Jaramillo, M. C., Zhang, D. D. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes & development 27, 2179-2191, doi: 10.1101/gad.225680.113 (2013).
3. Rotblat, B., Melino, G., Knight, R. A. Nrf2 and p53: Januses in cancer Oncotarget 3, 1272-1283 (2012).
4. Sporn, M. B., Liby, K. T. Nrf2 and cancer: the good, the bad and the importance of context. Nature reviews. Cancer 12, 564-571, doi: 10.1038/nrc3278 (2012).
5. Dinkova-Kostova, A. T. et al. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proceedings of the National Academy of Sciences of the United States of America 99, 11908-11913, doi: 10.1073/pnas.172398899 (2002).
6. Levonen, A. L. et al. Cellular mechanisms of redox cell signalling: role of cysteine modification in controlling antioxidant defences in response to electrophilic lipid oxidation products. The Biochemical journal 378, 373-382, doi: 10.1042/BJ20031049 (2004).
7. Jaiswal, A. K. Nrf2 signaling in coordinated activation of antioxidant gene expression. Free radical biology & medicine 36, 1199-1207, doi: 10.1016/j.freeradbiomed.2004.02.074 (2004).
8. Nguyen, T., Nioi, P., Pickett, C. B. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. The Journal of biological chemistry 284, 13291-13295, doi: 10.1074/jbc.R900010200 (2009).
9. Venugopal, R., Jaiswal, A. K. Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proceedings of the National Academy of Sciences of the United States of America 93, 14960-14965 (1996).
10. Venugopal, R., Jaiswal, A. K. Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes. Oncogene 17, 3145-3156, doi: 10.1038/sj. onc.1202237 (1998).
11. DeNicola, G. M. et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475, 106-109, doi: 10.1038/nature10189 (2011).
12. Hayes, J. D., McMahon, M. Nrf2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends in biochemical sciences 34, 176-188, doi: 10.1016/j.tibs.2008.12.008 (2009).
13. Moon, E. J., Giaccia, A. Dual roles of Nrf2 in tumor prevention and progression: Possible implications in cancer treatment. Free radical biology & medicine, doi: 10.1016/j.freeradbiomed.2014.11.009 (2014).
14. Padmanabhan, B. et al. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Molecular cell 21, 689-700, doi: 10.1016/j.molcel.2006.01.013 (2006).
15. Ramos-Gomez, M. et al. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proceedings of the National Academy of Sciences of the United States of America 98, 3410-3415, doi: 10.1073/pnas.051618798 (2001).
16. Thimmulappa, R. K. et al. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer research 62, 5196-5203 (2002).
17. Shelton, P., Jaiswal, A. K. The transcription factor NF-E2-related factor 2 (Nrf2): a protooncogene FASEB journal: official publication of the Federation of American Societies for Experimental Biology 27, 414-423, doi: 10.1096/fj.12-217257 (2013).
18. Taguchi, K., Motohashi, H., Yamamoto, M. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes to cells: devoted to molecular & cellular mechanisms 16, 123-140, doi: 10.1111/j.1365-2443.2010.01473.x (2011).
19. Geismann, C., Arlt, A., Sebens, S., Schafer, H. Cytoprotection "gone astray": Nrf2 and its role in cancer. OncoTargets and therapy 7, 1497-1518, doi: 10.2147/OTT.S36624 (2014).
20. Namani, A., Li, Y., Wang, X. J., Tang, X. Modulation of Nrf2 signaling pathway by nuclear receptors: implications for cancer. Biochimica et biophysica acta 1843, 1875-1885, doi: 10.1016/j.bbamcr.2014.05.003 (2014).
21. Mitsuishi, Y. et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer cell 22, 66-79, doi: 10.1016/j.ccr.2012.05.016 (2012).
22. Edgar, R., Domrachev, M., Lash, A. E. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic acids research 30, 207-210 (2002).
23. Kanehisa, M., Goto, S., Kawashima, S., Okuno, Y., Hattori, M. The KEGG resource for deciphering the genome. Nucleic acids research 32, D277-280, doi: 10.1093/nar/gkh063 (2004).
24. Sanchez-Palencia, A. et al. Gene expression profiling reveals novel biomarkers in nonsmall cell lung cancer. International journal of cancer. Journal international du cancer 129, 355-364, doi: 10.1002/ijc.25704 (2011).
25. Lu, T. P. et al. Identification of a novel biomarker, SEMA5A, for non-small cell lung carcinoma in nonsmoking women. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 19, 2590-2597, doi: 10.1158/1055-9965.EPI-10-0332 (2010).
26. Lee, E. S. et al. Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression. Clinical cancer research : an official journal of the American Association for Cancer Research 14, 7397-7404, doi: 10.1158/1078-0432.CCR-07-4937 (2008).
27. Bild, A. H. et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439, 353-357, doi: 10.1038/nature04296 (2006).
28. Yamauchi, M. et al. Epidermal growth factor receptor tyrosine kinase defines critical prognostic genes of stage I lung adenocarcinoma. PloS one 7, e43923, doi: 10.1371/journal.pone.0043923 (2012).
29. Botling, J. et al. Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation. Clinical cancer research: an official journal of the American Association for Cancer Research 19, 194-204, doi: 10.1158/1078-0432.CCR-12-1139 (2013).
30. Der, S. D. et al. Validation of a histology-independent prognostic gene signature for early-stage, non-small-cell lung cancer including stage IA patients. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 9, 59-64, doi: 10.1097/JTO.0000000000000042 (2014).
31. Venet, D., Dumont, J. E., Detours, V. Most random gene expression signatures are significantly associated with breast cancer outcome. PLoS computational biology 7, e1002240, doi: 10.1371/journal.pcbi.1002240 (2011).
32. Xiang, M., Namani, A., Wu, S., Wang, X. Nrf2: bane or blessing in cancer Journal of cancer research and clinical oncology 140, 1251-1259, doi: 10.1007/s00432-014-1627-1 (2014).
33. Lu, H., Ouyang, W., Huang, C. Inflammation, a key event in cancer development. Molecular cancer research: MCR 4, 221-233, doi: 10.1158/1541-7786.MCR-05-0261 (2006).
34. Singh, A. et al. Dysfunctional KEAP1-Nrf2 interaction in non-small-cell lung cancer. PLoS medicine 3, e420, doi: 10.1371/journal.pmed.0030420 (2006).
35. Bauer, A. K., Hill, T., 3rd & Alexander, C. M. The involvement of Nrf2 in lung cancer. Oxidative medicine and cellular longevity 2013, 746432, doi: 10.1155/2013/746432 (2013).
36. Jemal, A. et al. Global cancer statistics. CA: a cancer journal for clinicians 61, 69-90, doi: 10.3322/caac.20107 (2011).
37. Roh, M. S. Molecular pathology of lung cancer: current status and future directions. Tuberculosis and respiratory diseases 77, 49-54, doi: 10.4046/trd.2014.77.2.49 (2014).
38. Sonnenschein, C., Soto, A. M., Rangarajan, A., Kulkarni, P. Competing views on cancer. Journal of biosciences 39, 281-302 (2014).
39. Plomin, R., Haworth, C. M., Davis, O. S. Common disorders are quantitative traits. Nature reviews. Genetics 10, 872-878, doi: 10.1038/nrg2670 (2009).
40. Greenman, C. et al. Patterns of somatic mutation in human cancer genomes. Nature 446, 153-158, doi: 10.1038/nature05610 (2007).
41. McFarland, C. D., Mirny, L. A., Korolev, K. S. Tug-of-war between driver and passenger mutations in cancer and other adaptive processes. Proceedings of the National Academy of Sciences of the United States of America 111, 15138-15143, doi: 10.1073/pnas.1404341111 (2014).
42. Fidler, I. J. The organ microenvironment and cancer metastasis. Differentiation; research in biological diversity 70, 498-505, doi: 10.1046/j.1432-0436.2002.700904.x (2002).
43. Sleeman, J. P. The metastatic niche and stromal progression. Cancer metastasis reviews 31, 429-440, doi: 10.1007/s10555-012-9373-9 (2012).
44. Soto, A. M., Sonnenschein, C. The tissue organization field theory of cancer: a testable replacement for the somatic mutation theory. BioEssays: news and reviews in molecular, cellular and developmental biology 33, 332-340, doi: 10.1002/bies.201100025 (2011).
45. Zhou, T., Wang, T., Garcia, J. G. Expression of nicotinamide phosphoribosyltransferase-influenced genes predicts recurrencefree survival in lung and breast cancers. Scientific reports 4, 6107, doi: 10.1038/srep06107 (2014).
46. Zhou, T., Wang, T., Garcia, J. G. Genes influenced by the non-muscle isoform of Myosin light chain kinase impact human cancer prognosis. PloS one 9, e94325, doi: 10.1371/journal.pone.0094325 (2014).
47. Rahman, M. A. et al. RRM2 regulates Bcl-2 in head and neck and lung cancers: a potential target for cancer therapy. Clinical cancer research: an official journal of the American Association for Cancer Research 19, 3416-3428, doi: 10.1158/1078-0432.CCR-13-0073 (2013).
48. Wang, L., Meng, L., Wang, X. W., Ma, G. Y., Chen, J. H. Expression of RRM1 and RRM2 as a novel prognostic marker in advanced non-small cell lung cancer receiving chemotherapy. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine 35, 1899-1906, doi: 10.1007/s13277-013-1255-4 (2014).
49. Zhao, H., Zhang, H., Du, Y., Gu, X. Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine 35, 12679-12688, doi: 10.1007/s13277-014-2592-7 (2014).
50. Tusher, V. G., Tibshirani, R., Chu, G. Significance analysis of microarrays applied to the ionizing radiation response. Proceedings of the National Academy of Sciences of the United States of America 98, 5116-5121, doi: 10.1073/pnas.091062498 (2001).
51. Taylor, J., Tibshirani, R., Efron, B. The 'miss rate' for the analysis of gene expression data. Biostatistics 6, 111-117, doi: 10.1093/biostatistics/kxh021 (2005).